Agilent Technologies reported Q2 2025 results with USD 1.668 billion in revenue, representing a 6.0% year-over-year increase but a 0.8% decline quarter-over-quarter. Gross profit was USD 866 million, producing a gross margin of 51.9%, while operating income was USD 300 million (operating margin ~18.0%). Net income stood at USD 215 million and diluted earnings per share (EPS) was USD 0.75. The quarter delivered solid top-line momentum, but profitability was pressured by mix and relative expense discipline, leading to material sequential softness on the bottom line. Free cash flow was USD 107 million on USD 221 million of cash flow from operations, and Agilent ended the quarter with a cash balance of USD 1.49 billion. On the balance sheet, total assets reached USD 12.16 billion with total liabilities of USD 6.02 billion and shareholders’ equity of USD 6.14 billion. Net debt stood at USD 2.01 billion, reflecting a leverage profile that remains manageable within the tech-enabled life sciences equipment space. The company continued to reinvest in R&D (USD 112 million in the period) and maintained a conservative capital allocation stance, including share repurchases (USD 165 million) and dividends (USD 70 million).